Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
0.09% $23.01
America/New_York / 8 mar 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 865.08 mill |
EPS: | -1.530 |
P/E: | -15.04 |
Earnings Date: | Aug 08, 2023 |
SharesOutstanding: | 37.60 mill |
Avg Daily Volume: | 1.130 mill |
RATING 2024-03-07 |
---|
A- |
Buy |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -15.04 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-2.56x |
Company: PE -15.04 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 22.63 - 23.39 ( +/- 1.64%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 395 783 | Common Stock |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 10 000 | 8.000% Series A Redeemable Preferred Stock |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 299 430 | Common Stock Warrant (Right to Buy) |
2024-03-11 | New Leaf Biopharma Opportunities Ii, L.p. | Sell | 85 750 | Common Stock Warrant (Right to Buy) |
2024-03-11 | Silvernail Lauren P | Sell | 5 000 | Common Stock |
INSIDER POWER |
---|
75.63 |
Last 96 transactions |
Buy: 30 137 007 | Sell: 5 308 481 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $23.01 (0.09% ) |
Volume | 6.40 mill |
Avg. Vol. | 1.130 mill |
% of Avg. Vol | 566.75 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $22.35 | N/A | Active |
---|
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian and pancreatic cancer, and other mesothelin-expressing tumors. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate its proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.